Halozyme Therapeutics (HALO) Advances +31.8% in the Past 30 Days on Q2 Momentum
Key Takeaways
- Halozyme Therapeutics (HALO) rose roughly 31.8% over the last 30 days, climbing from about $83.23 to $109.66.
- The move was driven primarily by record second-quarter 2026 results, raised full-year guidance, and accelerated share repurchases.
- Royalty revenue from the ENHANZE drug-delivery platform grew 50% year over year, powered by partner products such as DARZALEX SC and VYVGART Hytrulo.
- Over the last quarter, the stock has gained more than 50%, extending a multi-month upward trend.
- Ongoing patent litigation with Merck and partner-concentration risk remain key items for investors to monitor.
Halozyme Therapeutics (HALO) Company Background and Market Position
Halozyme Therapeutics is a biopharmaceutical company best known for its ENHANZE drug-delivery technology, which uses a proprietary recombinant human hyaluronidase enzyme (rHuPH20) to enable drugs traditionally given by intravenous infusion to be administered as rapid subcutaneous injections. The company generates a growing stream of high-margin royalty revenue from partnered products built on ENHANZE, complemented by its own commercial products, Hylenex and Xyosted. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ENHANZE-enabled therapies from partners include Johnson & Johnson (JNJ)’s DARZALEX SC, argenx (ARGX)’s VYVGART Hytrulo, and Roche's Phesgo, alongside newer launches such as Ocrevus Zunovo, Opdivo Qvantig from Bristol Myers Squibb (BMY), and Rybrevant SC. Halozyme is also advancing Hypercon, a second platform targeting highly concentrated subcutaneous formulations, positioning the company for a broader, longer-term royalty opportunity. Investors follow the stock for its durable royalty model, strong margins, and compounding growth from a diversified portfolio of partnered biologics.
Halozyme Therapeutics (HALO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HALO advanced from a closing price of approximately $83.23 to $109.66, a gain of about 31.8%. The bulk of that move occurred in a single session in early August, when shares jumped more than 20% following the company's second-quarter earnings release and upgraded outlook. The momentum extended through the rest of the month, with the stock consolidating in a range above $100 rather than giving back its gains.
Over the last quarter, the performance is even more pronounced: from roughly $71 in early June to about $110, HALO has risen more than 50%, reflecting sustained strength in royalty revenue and repeated upward revisions to full-year guidance.
What Drove HALO Stock Price in the Last 30 Days
The primary catalyst was Halozyme's second-quarter 2026 earnings report, released on August 6, 2026. The company delivered record results that exceeded analyst expectations across the board: total revenue rose 48% year over year to $481 million, royalty revenue climbed 50% to $307.7 million, adjusted EBITDA increased 46% to $328.8 million, and non-GAAP diluted earnings per share reached $2.28, up from $1.54 a year earlier.
Halozyme also raised its full-year 2026 guidance, lifting total revenue to a range of $1.835 billion to $1.91 billion, royalty revenue to $1.22 billion to $1.245 billion, and non-GAAP EPS to $8.65 to $9.00. Management attributed the strength to continued uptake of established products such as DARZALEX SC and VYVGART Hytrulo, combined with rapidly growing contributions from newer launches. The company also completed $750 million in share repurchases and signed five new collaboration and licensing agreements, expanding ENHANZE into antibody-drug conjugates and nucleic acid therapies. The combination of a top- and bottom-line beat, higher guidance, and aggressive capital returns drove the sharp re-rating in the stock.
What Drove HALO Stock Performance Over the Last Quarter
Halozyme's multi-month advance reflects a broader narrative of accelerating royalty diversification and compounding platform economics. Through the spring and summer, the company announced new ENHANZE and Hypercon partnerships with GSK, Incyte, Vertex, and Oruka, while partner products such as VYVGART Hytrulo posted triple-digit royalty growth. These developments reinforced confidence in management's 2026-to-2028 financial targets and beyond. From what I see, the broadening revenue base has been a key support for the stock's steady climb.
The Hypercon platform, acquired through Elektrofi, has emerged as a second growth engine, with preparations underway for first clinical starts expected in 2027. Rising contributions from recently launched products have reduced the company's historical reliance on a small number of franchises, even as DARZALEX SC royalty revenue continued to grow.
HALO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on the sustainability of royalty growth from recently launched ENHANZE products, including conversion rates for subcutaneous formulations such as Opdivo Qvantig and Rybrevant SC. The company's third-quarter earnings, expected later in 2026, will test whether the second-half royalty step-up implied by guidance remains on track.
Other factors to monitor include progress on the Hypercon clinical timeline, the pace of new collaboration agreements, and the outcome of patent litigation with Merck (MRK) concerning ENHANZE technology, where U.S. appeals could resolve before year-end. Partner concentration, reimbursement dynamics, and broader biotech sector sentiment remain additional risks that could influence the stock's trajectory. I’m watching this closely as the litigation outcome could shape the longer-term outlook.
Exploring Tickeron AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Trading Bots to cross-check signals and explore systematic approaches alongside traditional analysis. These tools help surface patterns across thousands of tickers without replacing fundamental review. They provide a useful complement when evaluating momentum names like this one, especially when scanning for comparable setups in the biotech space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
HALO saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for HALO moved out of overbought territory on August 31, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In of the 59 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HALO moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HALO broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 327 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 301 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (85.470) is normal, around the industry mean (20.183). P/E Ratio (31.589) is within average values for comparable stocks, (27.671). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.520). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (7.911) is also within normal values, averaging (441.890).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement